It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).
It is very uncertain whether rifampicin changes active TB compared with isoniazid (very low certainty).
Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).